What are biomarkers?

被引:1274
作者
Strimbu, Kyle [1 ]
Tavel, Jorge A. [1 ]
机构
[1] NIAID, Div Clin Res, NIH, Bethesda, MD 20892 USA
关键词
biomarkers; clinical endpoints; surrogate endpoints; SURROGATE END-POINTS; CLINICAL-TRIALS; ENDPOINTS;
D O I
10.1097/COH.0b013e32833ed177
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Purpose of review This article provides working definitions and a conceptual framework to understand the roles of biomarkers in clinical research. Recent findings The definitions of the terms discussed in this article - medical signs, symptoms, biomarkers, surrogate endpoints, clinical endpoints, validation - are still under discussion, as are their relationships to each other, but broad consensus has developed in the past decade and a half about the necessity of distinguishing between, in particular, surrogate and clinical endpoints. Summary This article outlines the major definitions of the key terms in this field and considers select cases in which misunderstandings about the terms led to flawed research conclusions.
引用
收藏
页码:463 / 466
页数:4
相关论文
共 11 条
[1]   Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].
Atkinson, AJ ;
Colburn, WA ;
DeGruttola, VG ;
DeMets, DL ;
Downing, GJ ;
Hoth, DF ;
Oates, JA ;
Peck, CC ;
Schooley, RT ;
Spilker, BA ;
Woodcock, J ;
Zeger, SL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95
[2]  
D'Agostino Ralph B Jr, 2000, Curr Control Trials Cardiovasc Med, V1, P76, DOI 10.1186/CVM-1-2-076
[3]  
DEGRUTTOLA D, 1997, J INFECT DIS, V127, P237
[4]   SURROGATE ENDPOINTS IN CLINICAL-TRIALS - CANCER [J].
ELLENBERG, SS ;
HAMILTON, JM .
STATISTICS IN MEDICINE, 1989, 8 (04) :405-413
[5]   Surrogate end points in clinical trials: Are we being misled? [J].
Fleming, TR ;
DeMets, DL .
ANNALS OF INTERNAL MEDICINE, 1996, 125 (07) :605-613
[6]  
Food and Drug Administration, 2004, INN STAGN CHALL OPP
[7]   Controversies surround heart drug study questions about Vytorin and trial sponsors' conduct [J].
Mitka, Mike .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 299 (08) :885-887
[8]  
Strimbu K., 2001, ENVIRON HEALTH-GLOB, V5, P144
[9]  
The International Chronic Granulomatous Disease Cooperative Study Group, 1991, N ENGL J MED, V324, P509
[10]   SURROGATE ENDPOINTS IN CLINICAL-TRIALS - CARDIOVASCULAR-DISEASES [J].
WITTES, J ;
LAKATOS, E ;
PROBSTFIELD, J .
STATISTICS IN MEDICINE, 1989, 8 (04) :415-425